Frontier Pharma Pain-Identifying and Commercializing First-in-Class Innovation

1
Frontier Pharma Pain-Identifying and
Commercializing First-in-Class Innovation
Published on February - 2015
2
.
Report Overview
About Frontier Pharma Pain-Identifying and
Commercializing First-in-Class Innovation Research
Beam added a report Frontier Pharma
Pain-Identifying and Commercializing
First-in-Class Innovation. Description Large
and Innovative Pipeline. The active pain pipeline
is populated by 796 products across all stages of
development, which exhibit a highly diverse range
of molecular targets. GBI Researchs analyses
identified 122 first-in-class programs in active
development, constituting 13.6 of the pipeline
and acting on 65 first-in-class molecular
targets, indicating a high degree of innovation.
This is in stark contrast to the pain
therapeutics market, which has been largely
characterized by only incremental product
innovation over the last decade, as most market
segments continue to be dominated by
long-established active pharmaceutical
ingredients and the concomitant mechanisms of
action. Get Full Details On http//www.research
beam.com/frontier-pharma-pain-identifying-and-comm
ercializing-first-in-class-innovation-market

3
.
Report Overview
Moderate-to-severe pain continues to be dominated
by opioids that are increasingly being
reformulated to offer abuse-resistance, while
mild pain is effectively treated with
Non-Steroidal Anti-Inflammatory Drugs (NSAID).
However, significant unmet needs remain, as
chronic pain and some neuropathic pain subtypes
do not respond well to existing therapies, which
are not adequate to treat associated
hypersensitization and do not align to the
underlying molecular pathophysiological
profile. Despite being mostly distributed in the
early stages of development, first-in-class
innovation is particularly concentrated on novel
molecular targets that are aligned to the central
sensitization associated with neuropathic pain,
which is arguably the most debilitating and
difficult-to-treat type of chronic pain. This
gives them the potential to transform the future
market by expanding the range of drug
classes. Highly Diversified Range of Innovative
Programs in Early Pipeline and in Granted
Patents Pain is a complex and multifaceted
disorder with a complex interplay between
different pathological processes, and different
pain subtypes exhibit distinct underlying
etiologies and pathophysiologies. While
technological advances and extensive research
efforts have furthered the understanding of
4
.
Report Overview
these complex underpinnings, gaps remain.
However, these insights have translated into the
expanding pool of novel therapeutic targets, as
reflected by the highly innovative pipeline. GBI
Researchs proprietary analysis shows that
early-stage, first-in-class programs exhibit a
higher level of diversity with respect to novel
therapeutic targets. The significant diversity in
terms of targets is a reflection of the complex
underpinnings of distinct pain subtypes. Although
the pipeline continues to feature established
therapies, the range of mechanisms of action
employed by novel compounds is extremely diverse,
with the vast majority residing in the
Preclinical stage. This innovation and diversity
is maintained throughout the pipeline from early-
to late-stage development, although the degree of
innovation diminishes from Phase II.
Additionally, although NSAIDs and opioids remain
the cornerstone of pain treatment, GBI Research
analysis indicates a shift towards pain subtypes
that are more difficult to treat. Encouragingly,
these first-in-class compounds often target
molecules which are strongly implicated in pain
and its associated signaling pathways. Although
there are significant differentiations in the
scientific rationale and clinical prospects
across these first-in-class products, the
majority demonstrate significant Preclinical
evidence and alignment to molecular
pathophysiological changes.
5
Report Overview
In addition, GBI Researchs comprehensive and
complementary analysis of granted patents
highlighted a significant number of
first-in-class product technologies, many of
which have not been identified in the pain
product pipelines or even in pipelines across the
industry. The distribution of these products
across the molecular target super families and
families highlighted that they predominantly
align with the proportional distribution observed
across the pain pipeline, with G-protein-coupled
receptors and enzymes inhibitors constituting the
two major categories. However, an array of novel
molecular targets within those groups has been
identified, which do not present in any pipeline
or marketed products across the industry. A
significant degree of innovation has also been
identified in other molecular target
categories.   Active Deals Landscape with
Numerous Investment Opportunities The pain deals
landscape has been highly active over the past
eight years, with 261 licensing deals and 112
co-development deals. However, despite high
levels of investment activity, deals for
first-in-class products have been relatively
rare.
6
Report Overview

• Overall, more than 50 of deals involving
  first-in-class targets were settled in the early
  stages of development, which is a striking
  contrast with non-first-in-class products, which
  are more frequently entered into deals in the
  later stages of development. This reflects
  companies willingness to invest despite the
  high-risk profile of first-in-class products.
• With 107 first-in-class products available for
  strategic consolidations, a wide variety of
  investment opportunities are available for
  licensing deals or co-development deals in pain.
  This will be encouraged by the growing unmet need
  for chronic pain therapies, and an increased
  understanding of the distinct underlying
  pathophysiologies of distinct pain sub-types,
  allowed by technological advances. Among these,
  some first-in-class products have demonstrated
  promising Preclinical evidence and have
  significant potential to become game-changing
  products, representing high-reward investments.

7
Report Overview

• Scope
• The report covers and includes
• A brief introduction to pain, including the
  different subtypes of pain, pathophysiology, and
  overview of pharmacotherapy and treatment
  algorithms
• The changing molecular target landscape between
  market and pipeline and particular focal points
  of innovation in the pipeline
• A comprehensive review of the pipeline for
  first-in-class therapies, analyzed on the basis
  of stage of development, molecule type and
  molecular target
• Identification and assessment of first-in-class
  molecular targets with a particular focus on
  early-stage programs of which clinical utility
  has yet to be evaluated, as well as literature
  reviews on novel molecular targets
• Assessment of the licensing and co-development
  deal landscape for pain therapies and
  benchmarking of deals involving first-in-class
  versus non-first-in-class-products
•  
• Enquiry about this report _at_ http//www.researchbea
  m.com/frontier-pharma-asthma-identifying-and-comme
  rcializing-first-in-class-innovation-market/enquir
  e-about-report

8
Report Overview

• Reasons to Buy
• The report will assist business development and
  enable marketing executives to strategize their
  product launches, by allowing them to
• Understand the focal shifts in molecular targets
  in the pain therapeutics pipeline
• Understand the distribution of pipeline programs
  by phase of development, molecule type and
  molecular target
• Access a scientific and clinical analysis of
  first-in-class developmental programs for pain,
  benchmarked against non-first-in-class targets
• Access a list of the first-in-class therapies
  potentially open to deal-making opportunities
• Enquiry about this report _at_ http//www.researchbea
  m.com/frontier-pharma-pain-identifying-and-commerc
  ializing-first-in-class-innovation-market/enquire-
  about-report

9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/frontier-pharma-pain-i
dentifying-and-commercializing-first-in-class-inno
vation-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com